Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE)
Parker Knueppel, Seo Hyoun Bang, Camille Troyer, Alyssa Barriga, Jaekyu Shin, Christine Cadiz, Connie Abdo, Taylor McCart, Brittany Huynh, Craig Stevens, Crystal Zhou, Nuen Tsang Yang, Machelle Wilson, Tiffany Pon
Topics & Concepts
ApixabanMedicineEnd stage renal diseaseDialysisRenal functionRetrospective cohort studyInternal medicineClinical endpointSurgeryKidney diseaseRenal replacement therapyDosingDiseaseClinical trialRivaroxabanWarfarinAtrial fibrillationAtrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementHeparin-Induced Thrombocytopenia and Thrombosis